Purdue Pharma Announces Risk Strategy for ButransTM
Working with the Food and Drug Administration (FDA), Purdue Pharma L.P. has announced the development of a Risk Evaluation and Mitigation Strategy (REMS) for Butrans(tm) (buprenorphine) Transdermal System. The goals of the Butrans REMS Program are:
- To inform patients and healthcare professionals about the potential for abuse, misuse, and overdose from, and addiction to Butrans; and
- To inform patients and healthcare professionals about the safe use of Butrans
For more idetails visit www.butransrems.com<http://www.butransrems.com> which provides important information for healthcare professionals as well as patients and caregivers.
2014 OOA
Member Census
- FREE IT Services Checkup
- Chance to win $100 Visa Gift Card
- Access to other Members-only Benefits
Update Information Now
Contact Us
Call (855) 319-7828 todayto schedule a complimentary practice consultation.
An hour with our team could save you thousands of dollars!